FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis

The FDA has granted priority review to zasocitinib, a drug aimed at treating moderate to severe psoriasis, potentially accelerating its market entry.

This Wire brief sits within Fusion42's coverage of Medtech.